Smith & Nephew/£SN
07:00
15:10
23:15
07:25
15:30
1D1W1MYTD1Y5YMAX
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Ticker
£SN
Sector
Primary listing
LSE
Employees
17,000
Headquarters
Website
Smith & Nephew Metrics
BasicAdvanced
£11B
31.65
£0.42
0.67
£0.29
2.16%
Price and volume
Market cap
£11B
Beta
0.67
52-week high
£14.42
52-week low
£9.11
Average daily volume
4M
Dividend rate
£0.29
Financial strength
Current ratio
3.003
Quick ratio
1.402
Long term debt to equity
59.556
Total debt to equity
62.392
Dividend payout ratio (TTM)
66.60%
Interest coverage (TTM)
6.85%
Profitability
EBITDA (TTM)
1,075.736
Gross margin (TTM)
70.59%
Net profit margin (TTM)
8.26%
Operating margin (TTM)
16.60%
Effective tax rate (TTM)
19.11%
Revenue per employee (TTM)
£262,190
Management effectiveness
Return on assets (TTM)
5.81%
Return on equity (TTM)
9.14%
Valuation
Price to earnings (TTM)
31.654
Price to revenue (TTM)
2.597
Price to book
2.09
Price to tangible book (TTM)
7.92
Price to free cash flow (TTM)
19.365
Free cash flow yield (TTM)
5.16%
Free cash flow per share (TTM)
0.683
Dividend yield (TTM)
2.16%
Growth
Revenue change (TTM)
5.35%
Earnings per share change (TTM)
59.91%
3-year revenue growth (CAGR)
4.47%
10-year revenue growth (CAGR)
2.44%
3-year earnings per share growth (CAGR)
-0.44%
10-year earnings per share growth (CAGR)
-1.03%
3-year dividend per share growth (CAGR)
0.53%
10-year dividend per share growth (CAGR)
2.28%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Bulls say / Bears say
Smith & Nephew reaffirmed its full-year 2025 guidance for about 5 percent underlying revenue growth and a 19–20 percent trading profit margin after releasing Q1 results, highlighting management’s confidence in steady performance (Reuters).
The company secured a 10-year contract worth up to $75 million with the U.S. Department of Defense for its RENASYS TOUCH Negative Pressure Wound Therapy systems, strengthening the Advanced Wound Management portfolio and reinforcing product leadership (Reuters).
A $500 million share buyback program was announced for H2 2025, demonstrating strong free cash flow from the 12-Point Plan and a commitment to shareholder returns (Reuters).
US tariffs are expected to impose a net $15–20 million headwind on full-year 2025 results, which could squeeze trading profit margins despite solid underlying growth goals (Reuters).
Emerging Markets revenue slipped by 0.2 percent in Q2 2025, highlighting ongoing weakness in China even as other regions posted stronger gains (Smith & Nephew).
Margins in the Sports Medicine & ENT segment contracted by 130 basis points in H1 2025 due to headwinds from China’s Volume-Based Procurement (VBP), with a further ~$25 million revenue hit anticipated in H2 (Smith & Nephew).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Smith & Nephew stock?
Smith & Nephew (SN) has a market cap of £11B as of October 14, 2025.
What is the P/E ratio for Smith & Nephew stock?
The price to earnings (P/E) ratio for Smith & Nephew (SN) stock is 31.65 as of October 14, 2025.
Does Smith & Nephew stock pay dividends?
Yes, the Smith & Nephew (SN) stock pays dividends to shareholders. As of October 14, 2025, the dividend rate is £0.2858 and the yield is 2.16%. Smith & Nephew has a payout ratio of 66.6% on a trailing twelve-month basis.
When is the next Smith & Nephew dividend payment date?
The next Smith & Nephew (SN) dividend payment is scheduled for November 07, 2025.
What is the beta indicator for Smith & Nephew?
Smith & Nephew (SN) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.